Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus DIAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus DIAZEPAM.
CENTRAX vs DIAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Benzodiazepine that enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
10-30 mg orally, 3-4 times daily.
Anxiety: 2-10 mg PO BID-QID; Sedation/Muscle spasm: 5-10 mg IV/IM q3-4h PRN; Status epilepticus: 0.15-0.2 mg/kg IV (max 10 mg) q10-15 min PRN.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Clinical Note
moderateDiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Diazepam is combined with Fluticasone propionate."
Clinical Note
moderateFludiazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluticasone propionate."
Clinical Note
moderateDiazepam + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Diazepam."
Clinical Note
moderateTerminal half-life 30-56 hours (range 20-70 hours) in adults; prolonged in elderly (up to 100 hours), neonates (up to 100 hours), and cirrhosis (up to 100+ hours).
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal (70-80% as metabolites, primarily glucuronide conjugates; <5% unchanged), fecal (10-20% as metabolites), biliary (minor).
Category C
Category D/X
Benzodiazepine
Benzodiazepine
Diazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Diazepam."